Human hepatocyte-like cells and uses thereof

• US 20060154235A1
• Filed: 08/23/2005
• Published: 07/13/2006
• Est. Priority Date: 01/07/2005
• Status: Abandoned Application

• Current Assignee: Effector Cell Institute
• Original Assignee: Effector Cell Institute, Takahiro Ochiya
• Inventors: Teratani, Takumi, Ochiya, Takahiro
• Application Number:
  US11/210,337
• Publication Number:
  US 20060154235A1
• Time in Patent Office: Days
• US Class Current: 435/4
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 5/067 Hepatocytes
• CPC Class Codes: C12Q 1/18 Testing for antimicrobial activity of a material
• CPC Class Codes: G01N 2800/08 Hepato-biliairy disorders other than hepatitis
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/5038 involving detection of metabolites per se
• CPC Class Codes: G01N 33/5067 Liver cells

Abstract

The present invention provides modified methods of producing human hepatocyte-like cells which exhibit phenotypes more similar to those of human hepatocytes. The present invention also provides the human hepatocyte-like cells and uses thereof. The methods of the present invention comprises a prolonged incubation period and addition of dexamethasone to the culture medium. The methods of the inventors produce human hepatocyte-like cells whose morphology is more similar to that of human hepatocytes, compared with the conventional system. The cells produced have both morphological and functional features of primary culture cells from normal human liver, including cytochrome P450 (CYP), multi-drug resistance-associated protein (MRP), and multi-drug protein (MDR). The use of human hepatocyte-like cells of the present invention enables, without using any animal model, assessment of metabolism and hepatotoxicity of test compounds, which are drug candidates, and screening for therapeutic agents for hepatic diseases, inhibitors to hepatitis virus infection, and therapeutic agents for viral hepatitis.

Claims

1. A method for preparing human hepatocyte-like cells, which comprises the steps of:

(a) incubating undifferentiated cells derived from human in a culture medium containing a combination of growth factors selected from (i) to (iii) below;

(i) acidic fibroblast growth factor, fibroblast growth factor 4, and hepatocyte growth factor;

(ii) acidic fibroblast growth factor and a growth factor selected from the group consisting of activin A, epidermal growth factor, and β

-nerve growth factor; and

(iii) fibroblast growth factor 4 and a growth factor selected from the group consisting of activin A and hepatocyte growth factor;

;

(b) incubating the cells cultured in step (a) in a culture medium containing oncostatin M; and

(c) incubating the cells cultured in step (b) in a culture medium containing dexamethasone, wherein the total culturing period is about 2 to about 13 weeks.

2. The method according to claim 1, which comprises using a collagen-coated culture dish.

3. The method according to claim 1, wherein the undifferentiated cells derived from human are embryonic stem cells, adult stem cells, mesenchymal stem cells, cord blood cells, or somatic cells with artificially conferred multipotency.

4. Human hepatocyte-like cells prepared by the method according to any one of claims 1 to 3.

5. A therapeutic agent for hepatic diseases, which comprises the human hepatocyte-like cells according to claim 4.

6. A method for assessing the metabolism of a test compound, which comprises the steps of:

(a) contacting a test compound with the human hepatocyte-like cells according to claim 4;

and

(b) determining the metabolism of the test compound contacted with the human hepatocyte-like cells.

7. A method for assessing hepatotoxicity of a test compound, which comprises the steps of:

(a) contacting a test compound with the human hepatocyte-like cells according to claim 4;

and

(b) determining the degree of damage of the human hepatocyte-like cells contacted with the test compound.

8. A method of screening for a therapeutic agent for hepatic diseases, which comprises the steps of:

(a) contacting a test compound with the human hepatocyte-like cells according to claim 4;

(b) determining the function of the human hepatocyte-like cells contacted with the test compound; and

(c) selecting a compound that enhances the function of the human hepatocyte-like cells contacted with the test compound.

9. A method of screening for an inhibitor to hepatitis virus infection, which comprises the steps of:

(a) contacting the human hepatocyte-like cells according to claim 4 with hepatitis virus in the presence of a test compound;

(b) examining the infection of hepatitis virus to the human hepatocyte-like cells contacted with hepatitis virus; and

(c) selecting a compound that inhibits the infection of hepatitis virus.

10. A method of screening for a therapeutic agent for viral hepatitis, which comprises the steps of:

(a) contacting the human hepatocyte-like cells according to claim 4 with hepatitis virus;

(b) contacting a test compound with the human hepatocyte-like cells infected with hepatitis virus;

(c) determining the degree of hepatitis virus propagation in the cells contacted with the test compound; and

(d) selecting a compound that inhibits the propagation of hepatitis virus.